118 related articles for article (PubMed ID: 31064778)
1. RORγ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment.
Liu X; Zawidzka EM; Li H; Lesch CA; Dunbar J; Bousley D; Zou W; Hu X; Carter LL
Cancer Immunol Res; 2019 Jul; 7(7):1054-1063. PubMed ID: 31064778
[TBL] [Abstract][Full Text] [Related]
2.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
Garcia-Hernandez Mde L; Hamada H; Reome JB; Misra SK; Tighe MP; Dutton RW
J Immunol; 2010 Apr; 184(8):4215-27. PubMed ID: 20237297
[TBL] [Abstract][Full Text] [Related]
4. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12.
Tajima M; Wakita D; Satoh T; Kitamura H; Nishimura T
Int Immunol; 2011 Dec; 23(12):751-9. PubMed ID: 22039016
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
[TBL] [Abstract][Full Text] [Related]
6.
Flores-Santibáñez F; Cuadra B; Fernández D; Rosemblatt MV; Núñez S; Cruz P; Gálvez-Cancino F; Cárdenas JC; Lladser A; Rosemblatt M; Bono MR; Sauma D
Front Immunol; 2018; 9():209. PubMed ID: 29472932
[TBL] [Abstract][Full Text] [Related]
7. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.
Huber M; Heink S; Grothe H; Guralnik A; Reinhard K; Elflein K; Hünig T; Mittrücker HW; Brüstle A; Kamradt T; Lohoff M
Eur J Immunol; 2009 Jul; 39(7):1716-25. PubMed ID: 19544308
[TBL] [Abstract][Full Text] [Related]
8. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge.
Hamada H; Garcia-Hernandez Mde L; Reome JB; Misra SK; Strutt TM; McKinstry KK; Cooper AM; Swain SL; Dutton RW
J Immunol; 2009 Mar; 182(6):3469-81. PubMed ID: 19265125
[TBL] [Abstract][Full Text] [Related]
9. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
10. The inducible costimulator augments Tc17 cell responses to self and tumor tissue.
Nelson MH; Kundimi S; Bowers JS; Rogers CE; Huff LW; Schwartz KM; Thyagarajan K; Little EC; Mehrotra S; Cole DJ; Rubinstein MP; Paulos CM
J Immunol; 2015 Feb; 194(4):1737-47. PubMed ID: 25576595
[TBL] [Abstract][Full Text] [Related]
11. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
12. Tc17 CD8 T cells: functional plasticity and subset diversity.
Yen HR; Harris TJ; Wada S; Grosso JF; Getnet D; Goldberg MV; Liang KL; Bruno TC; Pyle KJ; Chan SL; Anders RA; Trimble CL; Adler AJ; Lin TY; Pardoll DM; Huang CT; Drake CG
J Immunol; 2009 Dec; 183(11):7161-8. PubMed ID: 19917680
[TBL] [Abstract][Full Text] [Related]
13. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
14. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
Helmich BK; Dutton RW
J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
[TBL] [Abstract][Full Text] [Related]
15. The development of IL-17/IFN-γ-double producing CTLs from Tc17 cells is driven by epigenetic suppression of Socs3 gene promoter.
Satoh T; Tajima M; Wakita D; Kitamura H; Nishimura T
Eur J Immunol; 2012 Sep; 42(9):2329-42. PubMed ID: 22674086
[TBL] [Abstract][Full Text] [Related]
16. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
17. Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal.
Tamang DL; Redelman D; Alves BN; Vollger L; Bethley C; Hudig D
Cytokine; 2006 Nov; 36(3-4):148-59. PubMed ID: 17188506
[TBL] [Abstract][Full Text] [Related]
18. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
[TBL] [Abstract][Full Text] [Related]
19. CD8(+) T cells with distinct cytokine-producing features and low cytotoxic activity in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps.
Ma J; Shi LL; Deng YK; Wang H; Cao PP; Long XB; Zhang XH; Liu Y; Zeng M; Liu Z
Clin Exp Allergy; 2016 Sep; 46(9):1162-75. PubMed ID: 27176491
[TBL] [Abstract][Full Text] [Related]
20. Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.
Hu X; Liu X; Moisan J; Wang Y; Lesch CA; Spooner C; Morgan RW; Zawidzka EM; Mertz D; Bousley D; Majchrzak K; Kryczek I; Taylor C; Van Huis C; Skalitzky D; Hurd A; Aicher TD; Toogood PL; Glick GD; Paulos CM; Zou W; Carter LL
Oncoimmunology; 2016; 5(12):e1254854. PubMed ID: 28123897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
